Excreted Unchanged %
Half-Life (Normalesrd) Hours
Plasma Protein Binding %
Volume Of Distribution L/Kg
Dose For Normal Renal Function
20-40 mg qhs
Adjustment For Renal Failure Method
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
50-75% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
10-50% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
10% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [A]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [B]
Campoli-Richards DM, Clissold SP. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986; 32: 197-221. [PMID: 2875864] / Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991; 21: 178-94. [PMID: 1764869] / Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR. Disposition of famotidine in renal insufficiency. J Clin Pharmacol. 1987; 27: 782-7. [PMID: 3429684] / Saima S, Echizen H, Yoshimoto K, Ishizaki T. Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. J Clin Pharmacol. 1990; 30: 159-62. [PMID: 2312768]
Toxicity Notes
CNS adverse effects have been reported in patients with moderate and severe renal insufficiency. Famotidine, unlike cimetidine, does not inhibit renal tubular secretion of creatinine.